Daewon Pharm (003220) — Cash Flow-to-Debt Ratio
Daewon Pharm (003220) has a Cash Flow-to-Debt Ratio of 0.09x as of December 2025, meaning its operating cash flow of ₩30.61 Billion could theoretically repay 0% of its total liabilities (₩339.07 Billion) in one year. See 003220 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Daewon Pharm Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Daewon Pharm across 15 annual periods. Also explore how fast is Daewon Pharm growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Daewon Pharm (2011–2025)
Year-by-year debt coverage analysis for Daewon Pharm. For market capitalisation and broader financial context, see Daewon Pharm stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | ₩42.31 Billion | ₩339.07 Billion | ▲ +24.2% |
| 2024 | 0.10x | ₩30.04 Billion | ₩298.81 Billion | ▼ -52.6% |
| 2023 | 0.21x | ₩51.73 Billion | ₩243.73 Billion | ▲ +30.4% |
| 2022 | 0.16x | ₩33.33 Billion | ₩204.78 Billion | ▲ +53.3% |
| 2021 | 0.11x | ₩22.41 Billion | ₩211.18 Billion | ▼ -47.9% |
| 2020 | 0.20x | ₩24.95 Billion | ₩122.44 Billion | ▼ -18.9% |
| 2019 | 0.25x | ₩30.97 Billion | ₩123.32 Billion | ▼ -42.1% |
| 2018 | 0.43x | ₩40.03 Billion | ₩92.24 Billion | ▲ +501.1% |
| 2017 | 0.07x | ₩4.27 Billion | ₩59.07 Billion | ▼ -81.7% |
| 2016 | 0.39x | ₩20.79 Billion | ₩52.67 Billion | ▼ -29.5% |
| 2015 | 0.56x | ₩25.82 Billion | ₩46.09 Billion | ▲ +48.0% |
| 2014 | 0.38x | ₩17.45 Billion | ₩46.11 Billion | ▲ +13.3% |
| 2013 | 0.33x | ₩12.32 Billion | ₩36.89 Billion | ▼ -17.4% |
| 2012 | 0.40x | ₩13.83 Billion | ₩34.20 Billion | ▼ -17.8% |
| 2011 | 0.49x | ₩17.93 Billion | ₩36.47 Billion | — |